Head-to-head · WeighScore
Center for Medical Weight Loss (CMWL) vs Omada Health
The verdict
Center for Medical Weight Loss (CMWL) takes it — 66.9/100 to 55.6/100.
Center for Medical Weight Loss (CMWL) grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Center for Medical Weight Loss (CMWL) runs a 100 percent online, physician-supervised GLP-1 program using compounded semaglutide and tirzepatide with flat any-dose pricing.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Center for Medical Weight Loss (CMWL) | Omada Health |
|---|---|---|
| WeighScore | 66.9/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #171 | #435 |
| Semaglutide | $149/mo (all doses, compounded) | Not disclosed |
| Tirzepatide | $239/mo (all doses, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #171 · C
Strengths
- Very competitive flat any-dose pricing (semaglutide from 116 dollars per month, tirzepatide from 159 dollars per month)
- Established Center for Medical Weight Loss brand with physician supervision and clinical support
- Fast 24-hour approvals and free three to five day shipping
Where it loses points
- Some states are ineligible and the eligible-state list is not published
- Compounding pharmacy is not named publicly
- Lowest per-month prices require a three-month prepaid commitment
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.